Oxytocin and Vasopressin Systems in Obesity and Metabolic Health: Mechanisms and Perspectives
Oxytocin and Vasopressin Systems in Obesity and Metabolic Health: Mechanisms and Perspectives
复制标题
DOI：
10.1007/s13679-019-00355-z
复制
发表时间：
2019-09-01
影响因子：
8.8
通讯作者：
Magkos, Faidon
中科院分区：
文献类型：
--
作者：
Ding, Cherlyn;Magkos, Faidon
综述目的神经垂体内分泌系统被认为是改善肥胖相关代谢功能障碍的潜在治疗靶点，因为它对肥胖所致的心理、神经和代谢系统具有多重效应。最近的发现精氨酸加压素前体的C末端部分铜绿素与体重指数和2型糖尿病的风险呈正相关。在肥胖和其他几种糖稳态异常的情况下，血浆催产素降低。最近的数据还显示，非经典组织，如心肌细胞、肝细胞和β细胞，表现出对催产素和加压素受体结合的反应，这可能有助于代谢功能的改变。摘要厌氧和增压素途径的调节似乎是催产素和加压素对体重调节作用的主要机制；然而，它们在直接药理学应用中存在明显的局限性。在考虑将任何一种系统用于治疗之前，需要更清楚地了解它们更广泛的生理影响。
Purpose of ReviewThe neurohypophysial endocrine system is identified here as a potential target for therapeutic interventions toward improving obesity-related metabolic dysfunction, given its coinciding pleiotropic effects on psychological, neurological and metabolic systems that are disrupted in obesity.Recent FindingsCopeptin, the C-terminal portion of the precursor of arginine-vasopressin, is positively associated with body mass index and risk of type 2 diabetes. Plasma oxytocin is decreased in obesity and several other conditions of abnormal glucose homeostasis. Recent data also show non-classical tissues, such as myocytes, hepatocytes and beta-cells, exhibit responses to oxytocin and vasopressin receptor binding that may contribute to alterations in metabolic function.SummaryThe modulation of anorexigenic and orexigenic pathways appears to be the dominant mechanism underlying the effects of oxytocin and vasopressin on body weight regulation; however, there are apparent limitations associated with their use in direct pharmacological applications. A clearer picture of their wider physiological effects is needed before either system can be considered for therapeutic use.